Dr. Sophie Kornowski, Chairperson and Senior Partner, Gurnet Point Capital
Dr. Kornowski and her team completed over 50 deals per year in her role as head of partnering at Roche. Previously, she led Roche’s major affiliate for five years in France. Dr. Kornowski also spent 11 years in various leadership roles at Merck in the United States, France and Israel. She spent the early years of her career at Abbott and Sanofi, in France and the United States. Dr. Kornowski has an MBA from the University of Chicago Booth and a PhD in Pharmacy from Paris Descartes University.
Gretchen McCarey, Director, Waypoint Capital
Prior to joining Waypoint, Ms. McCarey spent almost two decades working in the alternative asset management industry, with a heavy focus on venture capital. She spent seven years at Atlas Venture and its spin-off, Accomplice in VP, Finance and CFO positions. Preceding Atlas/Accomplice, she served in key financial roles as the Controller at Globespan Capital Partners and Corporate Controller at NVest Companies, L.P., now known as Natixis Global Asset Management. She began her finance career in the audit practice at Deloitte & Touche LLP. Ms. McCarey is a CPA and a member of the Private Equity CFO Association, the Financial Executives Alliance, and Boston’s Women in Alternative Assets. She received an MBA and MS in accounting, summa cum laude, from Northeastern University, and a BA, magna cum laude, from Colby College.
Peter D. Staple, Board Member
Prior to joining ALZA, Mr. Staple served in senior positions at Cetus and Chiron Corporations, where his responsibilities covered corporate partnering, licensing, mergers and acquisitions, and financings, including transactions involving commercialization of polymerase chain reaction, hepatitis C and HIV screening technologies. Prior to entering the biotechnology industry, Mr. Staple practiced corporate and securities law with Heller Ehrman LLP. Mr. Staple serves on the board of directors of Assertio Therapeutics, Inc., and has served multiple terms on the board of visitors at Stanford Law School. He holds B.A. and J.D. degrees from Stanford University.
Perry Sternberg, President and Chief Executive Officer
Before joining Shire in 2013, Mr. Sternberg served as Vice President & General Manager of U.S. and Canada Pharmaceuticals at Bausch & Lomb. Prior to that, Mr. Sternberg held various roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc.
Hallmarks of Mr. Sternberg’s business style and success are his unrelenting focus on exceeding the needs of customers and bringing out the optimal performance in his teams. Mr. Sternberg serves on the Board of Directors for BIO, MBR (Massachusetts Business Roundtable) and the Ophthalmology Innovation Summit. He holds a bachelor’s degree in Animal Bioscience from Pennsylvania State University.
Christopher A. Viehbacher, Managing Partner, Gurnet Point Capital
- Former Co-chair with Bill Gates, the CEO Roundtable on Neglected Diseases
- Past-Chairman of the CEO Roundtable on Cancer. Chairman of the Board of the Pharmaceutical Research and Manufacturers of America in Washington
- President of the European Federation of Pharmaceutical Industries and Associations in Brussels.
- Chair of the Health Governors at World Economic Forum and Co-chair of a WEF initiative to create a Global Charter for Healthy Living.
- Member of the International Business Council.
Mr. Viehbacher has in the past served on various advisory groups at MIT, Duke University and Queen’s University at Kingston, Ontario.
Mr. Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honor, the Legion d’Honneur.
Travis Wilson, Partner, Gurnet Point Capital
Mr. Wilson has extensive experience in biotechnology and venture investing, leading transactions from seed-investments to near commercial assets. For more than a decade, he was a member of the life science investment team at the Morningside Group, a privately-held investment firm. With Morningside, he assisted with multiple financings, including several public and private companies such as Chimerix (NASDAQ: CMRX), Genocea (NASDAQ: GNCA), BioVex (acquired by Amgen), Aduro (NASDAQ: ADRO) and Argos (NASDAQ: ARGS).
Mr. Wilson also served as a director and board member for nonclinical and clinical stage companies, providing operational and management support to a portfolio of companies developing drugs across a broad spectrum of therapeutic focus, including orphan diseases, cardio-renal disorders, oncology, cell-therapy and ophthalmology. He has lectured extensively on life science investing and management, and is a long-time supporter of patient-advocacy groups. Mr. Wilson holds a law degree and a chemical engineering degree, both from the University of Wisconsin.